Skip to main content

Meritxell Genesca Ferrer

I am a senior investigator at the infectious diseases department where I lead projects focused on defining protective immune responses against pathogens in order to develop new therapies. I have mainly worked on cervicovaginal mucosa immunity, a tissue with a high impact on public health as the portal of entry for sexually transmitted infections such as HIV. The knowledge acquired during my scientific career has served to expand my research towards the understanding of immune protection against pathogens in other tissues, such as against SARS-CoV-2 in the lung.

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

Meritxell Genesca Ferrer

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

I am a senior investigator at the infectious diseases department where I lead projects focused on defining protective immune responses against pathogens in order to develop new therapies. I have mainly worked on cervicovaginal mucosa immunity, a tissue with a high impact on public health as the portal of entry for sexually transmitted infections such as HIV. The knowledge acquired during my scientific career has served to expand my research towards the understanding of immune protection against pathogens in other tissues, such as against SARS-CoV-2 in the lung.

Dr. Meritxell Genescà is an expert on cervical mucosal immunology and infectious diseases. She obtained the Extraordinary Award from the Autonomous University of Barcelona as a Doctor in Veterinary Medicine (2000). After obtaining her PhD in physiology (2001-2004, IIBB-CSIC), she was contracted by the University of California first as a postdoctoral researcher and then as an Associate Researcher Immunologist. For the next six years, she worked on the top animal model for HIV sexual transmission studies and specialized in mucosal immunology. In 2011, she joined the Institut d’Investigació Germans Trias i Pujol in Badalona, through a Ramón y Cajal contract, before moving to her current institution in 2017. Dr. Genescà is interested on defining the nature of protective immune responses against pathogens that use the cervicovaginal mucosa as their portal of entry, such as HIV. Her group collaborates with several basic and clinical research groups in order to conduct translational comparative medicine in the following areas: 1) HIV reservoir characterization in the cervical tissue and new strategies for its elimination; 2) Sexually Transmitted Infections and increased risk of co-infection; 3) Adjuvants and biomarkers of mucosal immunity; 4) Tissue explant models to study host-pathogen interaction and immunity (including SARS-CoV-2).
She is a member of the international Society for Mucosal Immunology (SMI), the Spanish group for AIDS study (GESIDA) and the Spanish HIV/AIDS Network (RIS). Moreover, she has participated in many dissemination activities, such as career orientation and continuous education for seniors, among others. Her track record includes over 35 articles in major international scientific journals (https://orcid.org/0000-0001-6413-3812) with an h-index of 20, numerous presentations in international meetings and several fellowships and awards. She is also actively involved in teaching and student training.

Projects

Induction of CD8+ Resident Memory T cell phenotypes to eliminate viral reservoirs

IP: Meritxell Genesca Ferrer
Collaborators: -
Funding agency: Gilead Sciences, S.L.U.
Funding: 49997.2
Reference: GLD21-00049
Duration: 01/07/2022 - 31/12/2024

ISIDORe

IP: Meritxell Genesca Ferrer
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 4471.25
Reference: ISIDORE_HE-INFRA-EMERGENCY2021
Duration: 01/02/2022 - 31/07/2025

Enhancing CD8+ Resident Memory T cell function to control and eliminate viral reservoirs

IP: Meritxell Genesca Ferrer
Collaborators: Vicente Descalzo Jorro, Josep Castellví Vives, Laura Mañalich Barrachina
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI20/00160
Duration: 01/01/2021 - 30/06/2025

ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT)

IP: Inmaculada Fuentes Camps
Collaborators: Soledad Gallego Melcón, Fco Javier Santos Vicente, Gema Ariceta Iraola, Santiago Ramon y Cajal Agüeras, Marta Martínez Vicente, ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA, Manuel Comabella Lopez, Joan Sahuquillo Barris, Miguel Segura Ginard, Simon Schwartz Navarro, Anna Rosell Novel, Meritxell Genesca Ferrer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 177204.2
Reference: EQC2019-006309-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

More than 50 healthcare professionals and community agents in Benguela receive specialized training to improve the detection and support of women with perinatal disorders.

According to the results, the team highlights the need to use combinations of drugs to reactivate all HIV reservoirs and eliminate the virus from the different tissues where it remains silent.

Related professionals

Berta Saez Gimenez

Berta Saez Gimenez

Main researcher
Pneumology
Read more
José vicente Andres Peiro

José vicente Andres Peiro

Main researcher
Reconstructive Surgery of the Locomotor System
Read more
Sheila Garcia  Prado

Sheila Garcia Prado

Psychiatry, Mental Health and Addictions
Read more
Pedro Serrano Pérez

Pedro Serrano Pérez

Research technician
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.